Title:
Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
Author(s):
Scheibe, Franziska; Metz, Imke; Radbruch, Helena; Siebert, Eberhard; Wolf, Stefan; Köhnlein, Martin; Harms, Lutz; Meisel, Andreas
Year of publication:
2018
Available Date:
2019-04-10T07:06:12Z
Abstract:
Currently, 12 cases (including our patient) of autoimmune encephalitis/encephalopathy after daclizumab therapy in MS are known worldwide and led to voluntary withdrawal of marketing authorization for daclizumab by the manufacturer Biogen (press release from European Medicines Agency, 07.03.2018).
Our findings suggest that early recognition of DRESS even with CNS manifestations and swift treatment with steroids and/or plasma exchange are essential to improve the longterm outcome.
Part of Identifier:
ISSN (print): 2332-7812
Keywords:
dress syndrome
eosinophilia
daclizumab therapy
MS
DDC-Classification:
610 Medizin und Gesundheit
Publication Type:
Wissenschaftlicher Artikel
DOI of the Original Publication:
PubMed ID of the Original Publication:
Journaltitle:
Neurology: Neuroimmunology & Neuroinflammation
Publisher:
Wolters Kluwer
Department/institution:
Charité - Universitätsmedizin Berlin
